产品
编 号：F416311
分子式：C32H50O13
分子量：642.73
分子式：C32H50O13
分子量：642.73
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 64849-39-4
产品详情
生物活性：
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
体内研究：
Rubusoside (50-300 mg/kg; po; 单剂量) 在 OVA 诱导的实验性过敏性哮喘小鼠模型中发挥着抗炎和抗哮喘活性。并且， Rubusoside 抑制 OVA 引起肺组织中的 NF-κB 通路激活。Animal Model:Ovalbumin‐induced mice allergic asthma model
Dosage:50, 150, 300 mg/kg
Administration:po; mixed with PBS (phosphate-buffered saline, pH 7.4) 1 hr before OVA treatment (intraperitoneal injected with 20 μg OVA and intranasal spray 1% OVA solution from Day 21 to Day 23)
Result:Contributed to the decrease of inflammatory cytokines (TNF-α, IL-13, IL-6, IL-5, and IL-4) inside the BALF of mice with asthma.Led a decline of OVA-dependent IgE and IgG1 inside the serum was also noticed in these mice.Enhanced the mRNA level of Foxp3 inside the mice lung affected with asthma while decrease that of IL-17A, IL-23, and RORγt.
Rubusoside is a diterpene glycoside that is also a sweetener and solubilizer with anti-angiogenic, anti-cancer, anti-obesity, anti-allergic and anti-asthmatic effects. Rubusoside attenuates airway hyperresponsiveness and reduces inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing OVA (HY-W250978)-induced airway inflammation. Rubusoside also prevents palmitic acid-induced lipotoxicity in pancreatic INS-1 cells, reduces the transport of human glucose transporters GLUT-1 and fructose GLUT-5, and inhibits NF-κB and α-amylase (α-amylase).
体内研究：
Rubusoside (50-300 mg/kg; po; 单剂量) 在 OVA 诱导的实验性过敏性哮喘小鼠模型中发挥着抗炎和抗哮喘活性。并且， Rubusoside 抑制 OVA 引起肺组织中的 NF-κB 通路激活。Animal Model:Ovalbumin‐induced mice allergic asthma model
Dosage:50, 150, 300 mg/kg
Administration:po; mixed with PBS (phosphate-buffered saline, pH 7.4) 1 hr before OVA treatment (intraperitoneal injected with 20 μg OVA and intranasal spray 1% OVA solution from Day 21 to Day 23)
Result:Contributed to the decrease of inflammatory cytokines (TNF-α, IL-13, IL-6, IL-5, and IL-4) inside the BALF of mice with asthma.Led a decline of OVA-dependent IgE and IgG1 inside the serum was also noticed in these mice.Enhanced the mRNA level of Foxp3 inside the mice lung affected with asthma while decrease that of IL-17A, IL-23, and RORγt.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备